PTAB shoots down tenth I-MAK Gilead challenge
24-07-2018
Hepatitis C drugs face four patent challenges in India
15-02-2017
Hailshadow / iStockphoto.com
In India, a non-profit organisation and an advocacy group have united to take on a patent covering pibrentasvir, part of the drug combination that forms AbbVie’s hepatitis C product Mavyret.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
I-MAK, Delhi Network of Positive People, Indian Patent Office, AbbVie, hepatitis C, Mavyret, generics, obviousness,
